Given the multifaceted role of GSK-3βin the processes contributingto the onset and progression of Alzheimer’s disease, it representsan excellent biological target in the pursuit of disease treatment.The interest in GSK-3β led to the discovery of numerous distinctclasses of GSK-3β inhibitors.35,36 Certain GSK-3βinhibitors, such as tideglusib, effectively reduced brain levels oftau phosphorylation, amyloid deposition, neuronal cell death, andmemory deficits in animal models of AD.37,38 While theseinhibitors have progressed to phase II of clinical trials39−41 none have yet reached the market. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.